Ding Lieming: Ding Lieming is Chairman & CEO of Betta Pharmaceuticals, holding a M.D., enjoying the titles of representative of the 12th Session of NPC, American practicing pathologist, practical tutor of Zhejiang University and the special allowance awarded by the State Council. Mr. Ding was graduated from Medical School of University of Arkansas and returned to China at the end of 2002 to establish Zhejiang Betta Pharmaceuticals Co., Ltd. He was involved in The Recruitment Program of Global Experts of China in 2009; won the tiles of Innovative Talent Award of Overseas Chinese Community in 2010 and Outstanding Contribution Award of National Science and Technology Project Execution during the 11th Five-year Plan. In 2012, he was elected as the leader of new drug innovation and manufacturing and industrialization team of The Recruitment Program of Global Experts of China and managing director of Chinese Pharmaceutical Association, and won the title of Contribution Award to Innovation Team of Overseas Chinese Community; In 2013, he won the title of The 3rd Session of Outstanding Talent Award of Hangzhou City; In 2014, he won the titles of The 5th Session of National Outstanding Technical Expert, 2014 China Innovation Example Award and 2014 China Commercial Leader Award. In 2016, he was elected as the new director of China Pharmaceutical Industry Research and Development Association. 

Tan Fenlai: Tan Fenlai is senior VP and CMO of Betta Pharmaceuticals, holding a PhD degree. He was graduated from Medical School of University of Arkansas, used to engage in post-doctoral research in Cleveland Clinic and Medical School of University of Michigan in succession. In 2007, he returned to China and took the position of director of new drug R&D center, in charge of R&D and clinical research. He is ASCO member and ADA member; involved in the list of Hangzhou New Century 131 Excellent Young and Middle-aged Talent Training Program in 2008, The Recruitment Program of Global Experts of Zhejiang Province and the first batch of “specially invited experts” of Hangzhou city in 2010 and The Recruitment Program of Global Experts of China in 2013. 

Wang Jiabing: Wang Jiabing is VP and director of R&D Center of Betta Pharmaceuticals. He was graduated from University of Wisconsin-Madison, holding a PhD degree on organic chemistry; used to serve for Merck and AstraZeneca. He has engaged in the field of new drug R&D and management for 20 years, with the great experience of leading over 20 projects of new drug R&D, covering various cancers, central nervous system diseases, viral hepatitis, nephrosis, obesity, osteoporosis and other diseases. He has successfully promoted several projects to step into the stage of clinical research, acting as the key inventor of three clinical new drugs and five candidate clinical new drugs. He has made remarkable contributions to designing agonists, inhibitors and drugs to penetrate blood brain barriers; accumulated abundant practical experience with multiple patents for inventions and over 40 theses. Based on his prominent innovation capability, Wang Jiabing has been widely recognized by his international counterparts, with great leadership and management capability. He was involved in The Recruitment Program of Global Experts of China in 2017. 

Zhu Lingyu: Zhu Lingyu is senior adviser of Chairman of Betta Pharmaceuticals, mastering a PhD degree of Ohio State University majoring in biochemistry and a MBA of Ross Business School of University of Michigan. He once held the posts as manager and director of business expansion in large-scale pharmaceutical companies, e.g. ESPERION, JNJ, Pfizer and Xian-Janssen Pharmaceutical. He was involved in high-level overseas talents of Beijing Economic and Technological Development Zone. At present, he is in charge of project introduction, business cooperation and technical transfer in Betta Pharmaceuticals. He was involved in The Recruitment Program of Global Experts of China in 2014. 

Zhang Hancheng: Zhang Hancheng is a senior adviser of Chairman of Betta Pharmaceuticals, graduated from Rensselaer Polytechnic Institute. He once held the posts of President and joint founder of Lugate In., principal scientist and director of project R&D in JNJ. He has been engaging in the industry of innovative new drug R&D, management, business expansion and international cooperation in transnational pharmaceutical companies and world-known new drug R&D service companies for over 2 decades; has successfully guided the R&D of new drugs for angiosis, diabetes and complications; has made great contributions and accumulated abundant practical experience in protein kinase inhibitors, GPCR antagonists, protease inhibitors and anti-tumor epigenetic treatment. He was involved in The Recruitment Program of Global Experts of China in 2015.